Cargando…
Fibroblast Growth Factor 21 in Chronic Hepatitis C: A Potential Non-Invasive Biomarker of Liver Status upon Viral Eradication
Fibroblast growth factor 21 (FGF-21), previously recognized as a marker of liver damage and a potential drug target in non-alcoholic fatty liver disease (NAFLD), has unclear implications in hepatitis C virus (HCV) infections. This study aimed to investigate the relationship between FGF-21 levels and...
Autores principales: | Biagi, Filippo, Carlomagno, Francesco, Carbone, Martina, Veralli, Roberta, Vespasiani-Gentilucci, Umberto, Riva, Elisabetta, Manfrini, Silvia, Tuccinardi, Dario, De Santis, Adriano, Gnessi, Lucio, Watanabe, Mikiko |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10673401/ https://www.ncbi.nlm.nih.gov/pubmed/37999215 http://dx.doi.org/10.3390/metabo13111119 |
Ejemplares similares
-
Scientific evidence underlying contraindications to the ketogenic diet: An update
por: Watanabe, Mikiko, et al.
Publicado: (2020) -
Current Evidence to Propose Different Food Supplements for Weight Loss: A Comprehensive Review
por: Watanabe, Mikiko, et al.
Publicado: (2020) -
Boosting pigment epithelial-derived factor: a promising approach for the treatment of early portal hypertension
por: Vespasiani-Gentilucci, Umberto, et al.
Publicado: (2015) -
Baseline HOMA IR and Circulating FGF21 Levels Predict NAFLD Improvement in Patients Undergoing a Low Carbohydrate Dietary Intervention for Weight Loss: A Prospective Observational Pilot Study
por: Watanabe, Mikiko, et al.
Publicado: (2020) -
Rapid Weight Loss, Central Obesity Improvement and Blood Glucose Reduction Are Associated with a Stronger Adaptive Immune Response Following COVID-19 mRNA Vaccine
por: Watanabe, Mikiko, et al.
Publicado: (2022)